多发性骨髓瘤患者血清HMGB1、FIB、β2-MG表达特征及临床价值OA

Objective:To investigate the expression characteristics and clinical value of serum high mobility group protein B1(HMGB1),fibrinogen(FIB),and β2-microglobulin(β2-MG)in patients with multiple myeloma(MM).Methods:A total of 137 patients with MM were selected as the study group,and 137 healthy individuals un-dergoing physical examinations were selected as the control group.Among the study group,42 cases were in stage Ⅰ,30 cases in stage Ⅱ,and 65 cases in stage Ⅲ according to the ISS.The study group was followed up for 3 years and further divided into the survival group(93 cases)and the death group(44 cases)based on the survival status of MM patients.The levels of serum HMGB1,FIB,and β2-MG in each group were compared,and the influencing factors of prognosis in MM patients and the predictive value of the three for the prognosis of MM patients were analyzed.Re-sults:Compared with the control group,the serum levels of HMGB1,FIB,and β2-MG in the study group were higher(all P<0.05).The serum levels of HMGB1,FIB,and β2-MG in patients of different clinical stages increased with the advancement of the stage(all P<0.05).Compared with the survival group,the serum levels of HMGB1,FIB,and β2-MG in the death group were higher(all P<0.05).Serum levels of HMGB1,FIB,and β2-MG were influencing fac-tors for the prognosis of MM patients(all P<0.05).Serum levels of HMGB1,FIB,and β2-MG had certain predictive value for the death of MM patients,and the combined value of the three was higher(all P<0.05).Conclusion:Serum levels of HMGB1,FIB and β2-MG in MM patients are highly expressed,and they increase with the progression of the disease stage.The combination of these three indicators has a good predictive value for the prognosis of MM patients.